Drug intelligence / Profile preview

Keycell-IM

Development stage: Preclinical
Lead developer: EHL Bio
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intramuscular

Overview

**Keycell-IM** is an autologous, multi-immune-cell cancer therapy developed by EHL Bio. The product is prepared from a patient's peripheral blood by separately isolating T cells, natural killer cells, invariant natural killer T cells, and dendritic cells; the cells are activated using EHL Bio's culture process, cryopreserved, expanded, and administered as a combined anti-cancer cellular immunotherapy. EHL Bio describes the program as intended to enhance anti-tumor immune responses and address residual disease, recurrence, and metastasis. ([ehlbio.co.kr](https://www.ehlbio.co.kr/eng/include/page/rd/freezing.php))

Other names: KEYCELL-IM inj.Keycell-IMKeycell-IM Injection

Beyond the preview

Go deeper on Keycell-IM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keycell-IM.

Explore the full profile